What is the dosage of Blincyto?

Blincyto is available in 1 dosages, including 35 mcg Injection

What does Blincyto treat?

Blincyto treats Lymphoid Leukemia

What is Blincyto made of?

Blincyto contains blinatumomab which is a Bispecific CD19-directed CD3-directed T Cell Engager

How is Blincyto administered?

Blincyto is administered as a Injectable

What is Blincyto mechanism of action?

Blincyto mechanism of action is CD19-directed Antibody Interactions, CD3 Receptor Agonists or CD3-directed Antibody Interactions

Blincyto

(blinatumomab)

blinatumomab 0.035 MG Injection [Blincyto]

BLACK BOX WARNING

Dosage & administration

* For the treatment of MRD-positive B-cell Precursor ALL
* See Full Prescribing Information for recommended dose by patient weight and schedule.
* Hospitalization is recommended for the first 3 days of the first cycle and the first 2 days of the second cycle.
* Premedicate with prednisone or equivalent dexamethasone.

* For the treatment of Relapsed or Refractory B-cell Precursor ALL
* See Full Prescribing Information for recommended dose by patient weight and schedule.
* Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle.
* Premedicate with dexamethasone.

* Refer to Full Prescribing Information for important preparation and administration information.
* Administer as a continuous intravenous infusion at a constant flow rate using an infusion pump.
* See Section 2.5 for infusion over 24 hours or 48 hours.
* See Section 2.6 for infusion over 7 days using Bacteriostatic 0.9% Sodium Chloride Injection, USP (containing 0.9% benzyl alcohol). This option is not recommended for patients weighing less than 22 kg.

eficacy, safety & testing

Blincyto clinical details

Blincyto REMS

Mechanism of Action (MOA)

Dosing: Relapsed or Refractory CD19-positive B-cell Precursor ALL

Administration: Relapsed or Refractory CD19-positive B-cell Precursor ALL

Dose Preparation: Relapsed or Refractory CD19-positive B-cell Precursor ALL

Efficacy (Adults): Relapsed or Refractory CD19-positive B-cell Precursor ALL

Efficacy (Adults Ph+): Relapsed or Refractory CD19-positive B-cell Precursor ALL

Efficacy (Pediatric): Relapsed or Refractory CD19-positive B-cell Precursor ALL

Safety Profile (Adults): Relapsed or Refractory CD19-positive B-cell Precursor ALL

Safety Profile (Adults Ph+): Relapsed or Refractory CD19-positive B-cell Precursor ALL

Safety Profile (Pediatrics): Relapsed or Refractory CD19-positive B-cell Precursor ALL

Dosing: Minimal Residual Disease (+) ALL

Administration: Minimal Residual Disease (+) ALL

Dose Preparation: Minimal Residual Disease (+) ALL

Efficacy: Minimal Residual Disease (+) ALL

Safety Profile: Minimal Residual Disease (+) ALL

drug label

Blincyto prescribing information

Have more Blincyto questions?

Submit MSL Request

Learn More

Need to report a Blincyto issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Blincyto Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Benefits Verification

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Blincyto Financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Amgen Safety Net Foundation Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Blincyto Patient education

Getting started on Blincyto

NOT PROVIDED BY BRANDInstructions For Use: Relapsed or Refractory CD19-positive B-cell Precursor ALL

NOT PROVIDED BY BRANDInstructions For Use: Minimal Residual Disease (+) ALL